Aller au contenu principal

 Articles scientifiques

Targeted therapy for breast cancer in older patients.

Auteurs : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Dal Lago L
Année : 2020
Journal : J Geriatr Oncol
Volume : 11
Pages : 380-388

The added value of geriatric assessment in evaluating a patient's Health-Related Quality-of-Life: A study in =70-year-old early-stage invasive breast cancer patients.

Auteurs : Quinten C, Kenis C, Hamaker M, Coolbrandt A, Brouwers B, Dal Lago L, Neven P, Vuylsteke P, Debrock G, Van den Bulck H, Smeets A, Schöffski P, Wedding U, Wildiers H
Année : 2020
Journal : Eur J Cancer Care (Engl)
Pages : e13278

Use of granulocyte-colony stimulating factors in older patients: a review of recently published data.

Auteurs : Klastersky JA, Dal Lago L, Lalami Y
Année : 2020
Journal : Curr Opin Oncol
Volume : 32
Pages : 258-261

Anti-HER2 therapy for breast cancer in older patients.

Auteurs : Goldner M, Franzoi MA, Dal Lago L, Pondé N
Année : 2020
Journal : Future Oncol
Volume : 16
Pages : 1393-1407

Use of granulocyte-colony stimulating factors in older patients: a review of recently published data.

Auteurs : Klastersky JA, Dal Lago L, Lalami Y
Année : 2020
Journal : Curr Opin Oncol

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Auteurs : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Année : 2020
Journal : Breast Cancer Res Treat

HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology.

Auteurs : Brain E, Caillet P, de Glas N, Biganzoli L, Cheng K, Dal Lago L, Wildiers H
Année : 2019
Journal : J Geriatr Oncol
Volume : 10
Pages : 1003-1013

Advances in pain management for older patients with cancer.

Auteurs : Hachem GE, Rocha FO, Pepersack T, Jounblat Y, Drowart A, Dal Lago L
Année : 2019
Journal : Ecancermedicalscience
Volume : 13
Pages : 980

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.

Auteurs : Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E
Année : 2018
Journal : Lancet Oncol
Volume : 19
Pages : 323-336

The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged =70 with early stage invasive breast cancer.

Auteurs : Quinten C, Kenis C, Hamaker M, Coolbrandt A, Brouwers B, Dal Lago L, Neven P, Vuylsteke P, Debrock G, Van den Bulck H, Smeets A, Schöffski P, Bottomley A, Wedding U, Wildiers H
Année : 2018
Journal : J Geriatr Oncol
Volume : 9(2)
Pages : 152-162

Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Auteurs : Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH
Année : 2018
Journal : Ann Oncol
Volume : 29(2)
Pages : 405-417

Old age: An extra risk for febrile neutropenia?

Auteurs : Klastersky J, Dal Lago L
Année : 2017
Journal : J Geriatr Oncol
Volume : 8(2)
Pages : 84-85

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.

Auteurs : Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van den Bulck H, Smeets A, Bechter O, Kini Bailur J, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem G, Wildiers H
Année : 2016
Journal : Oncotarget
Volume : 7(21)
Pages : 29977-88

Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.

Auteurs : Pondé N, Dal Lago L, Azim HA Jr
Année : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(6)
Pages : 661-71

Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future

Auteurs : Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L
Année : 2016
Journal : World J Clin Infect Dis
Volume : 6(3)
Pages : 37-60

What is the role of informed decision-making?

Auteurs : Pondé N, Dal Lago L, Azim HA Jr
Année : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(9)
Pages : 893

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Auteurs : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Année : 2016
Journal : PLoS ONE
Volume : 11(7)
Pages : e0154009

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Auteurs : Deliens C, Deliens G, Filleul O, Pepersack T, Awada A, Piccart-Gebhart M, Praet JP, Dal Lago L
Année : 2016
Journal : J Geriatr Oncol
Volume : 7(6)
Pages : 463-70

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Auteurs : Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, + collaborators (among others :, Dal Lago L, de Azambuja E, Dabakuyo-Yonli TS
Année : 2015
Journal : Ann Oncol
Volume : 26(5)
Pages : 873-879.

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.

Auteurs : Pinto AC, Ferreira-Santos F, Dal Lago L, de Azambuja E, Pimentel FL, Piccart-Gebhart M, Razavi D
Année : 2014
Journal : Ecancermedicalscience
Volume : 8(null)
Pages : 425